FIELD: medicine. SUBSTANCE: method involves introducing liquid perfluororganic compound in the amount of 0.2-0.4 ml into vitreous body cavity. The perfluororganic compound is moved over the retina surface by changing eyeball position relative to the horizontal plane. When detecting a bleeding retinal blood vessel, argon endolaser coagulation is carried out through the injected perfluororganic compound ball. The latter is removed from the vitreous body cavity after completed hemostasis. EFFECT: reduced number of postoperative complications; enhanced effectiveness of treatment.
